Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy JD Sports Fashion (JD.) by Christopher Ruane in The Motley Fool
- Buy Taylor Wimpey (TW.) by Royston Wild in The Motley Fool
- Buy United Utilities Group (UU.) by UBS
- Buy Pennon Group (PNN) by UBS
- Outperform Mony Group (MONY) by RBC Capital
- Buy AltynGold (ALTN) by Steve Moore in ShareProphets
- Sector Perform NATWEST GROUP (NWG) by RBC Capital
- Outperform OSB Group (OSB) by RBC Capital
- Sector Perform HSBC Holdings (HSBA) by RBC Capital
- Outperform Close Brothers Group (CBG) by RBC Capital
- Sector Perform Lloyds Banking Group (LLOY) by RBC Capital
- Sector Perform Metro Bank Holdings (MTRO) by RBC Capital
- Outperform Barclays (BARC) by RBC Capital
- Avoid Vistry Group (VTY) by Steve Moore in ShareProphets
- Sell Jaywing (JWNG) by Steve Moore in ShareProphets
- Buy Greencoat Renewables (CDI) (GRP) by Malcolm Stacey in ShareProphets
- Avoid Kooth (KOO) by Steve Moore in ShareProphets
- Buy Jadestone Energy (JSE) by Gary Newman in ShareProphets
- Buy Atalaya Mining (ATYM) by Gary Newman in ShareProphets
- Neutral Vistry Group (VTY) by Davy
Nuformix (NFX) Share Price
Health Care Sector
NOTE: This is based on 8 open tips for Nuformix (NFX)
| Latest Bid : 0.04p | Latest Ask : 0.06p |
| High Today : 0.06p | Low Today : 0.05p |
| This Years High : 0.40p | This Years Low : 0.05p |
| Volume : 2,000,363 | MKT Cap : £0.71M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Nuformix (NFX) Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.Nuformix (NFX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | 77.27% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | 77.27% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | 78.26% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | 77.27% |
| Avoid | Steve Moore | Premium Only | 2022-12-13 14:00:00 13/12/2022 | 84.38% |
Nuformix (NFX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.04p | Latest Ask : 0.06p |
| High Today : 0.06p | Low Today : 0.05p |
| This Years High : 0.40p | This Years Low : 0.05p |
| Volume : 2,000,363 | MKT Cap : £0.71M |
Nuformix Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Nuformix Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | 77.27% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | 77.27% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | 78.26% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | 77.27% |
| Avoid | Steve Moore | Premium Only | 2022-12-13 14:00:00 13/12/2022 | 84.38% |